Malignant peripheral nerve sheath tumor historical perspective

Jump to navigation Jump to search

Malignant peripheral nerve sheath tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Malignant Peripheral Nerve Sheath Tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Malignant peripheral nerve sheath tumor historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Malignant peripheral nerve sheath tumor historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Malignant peripheral nerve sheath tumor historical perspective

CDC on Malignant peripheral nerve sheath tumor historical perspective

Malignant peripheral nerve sheath tumor historical perspective in the news

Blogs on Malignant peripheral nerve sheath tumor historical perspective

Directions to Hospitals Treating Malignant peripheral nerve sheath tumor

Risk calculators and risk factors for Malignant peripheral nerve sheath tumor historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]

Overview

NF1-like cutaneous tumor syndromes appeared in the literature in 1880s, when Friedrich von Recklinghausen published seminal observations detailing cutaneous tumors comprised of both neuronal and fibroblastic tissue finally termed as neurofibromas. In 2006, Yang et al demonstrated a critical neurofibroma microenvironment interaction that includes SCF-stimulated Nf1+/− mast cells potentiating Nf1+/− fibroblast functions.

Historical Perspective

  • In 18th century, NF1-like cutaneous tumor syndromes appeared in the literature. [1]
  • In 1880s, Friedrich von Recklinghausen published seminal observations detailing cutaneous tumors comprised of both neuronal and fibroblastic tissue finally termed as neurofibromas.
  • In 2006, Yang et al demonstrated a critical neurofibroma microenvironment interaction that includes SCF-stimulated Nf1+/− mast cells potentiating Nf1+/− fibroblast functions. [2]

References

  1. Morse RP (1999). "Neurofibromatosis type 1". Arch Neurol. 56 (3): 364–5. PMID 10190829.
  2. http://www.bloodjournal.org/content/116/2/157?sso-checked=true

Template:WH Template:WS